These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 32080121

  • 1. The maximum standardized uptake value and extent of peritoneal involvement may predict the prognosis of patients with recurrent ovarian cancer after primary treatment: A retrospective clinical study.
    Jiang Y, Hou G, Wu F, Zhu Z, Zhang W, Cheng W.
    Medicine (Baltimore); 2020 Feb; 99(8):e19228. PubMed ID: 32080121
    [Abstract] [Full Text] [Related]

  • 2. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
    Palomar Muñoz A, Cordero García JM, Talavera Rubio MDP, García Vicente AM, Pena Pardo FJ, Jiménez Londoño GA, Soriano Castrejón Á, Aranda Aguilar E.
    Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([18F] FDG) in the detection of recurrent ovarian cancer.
    Palomar Muñoz A, Cordero García JM, Talavera Rubio P, García Vicente AM, González García B, Bellón Guardia ME, Soriano Castrejón Á, Aranda Aguilar E.
    Med Clin (Barc); 2018 Aug 10; 151(3):97-102. PubMed ID: 29276012
    [Abstract] [Full Text] [Related]

  • 4. [Peritoneal carcinomatosis from ovarian cancer: role of 18F-FDG-PET/CT and CA125].
    Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Stabile Ianora AA, Giganti M, Niccoli Asabella A.
    Recenti Prog Med; 2012 Nov 10; 103(11):510-4. PubMed ID: 23096741
    [Abstract] [Full Text] [Related]

  • 5. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, Asabella AN.
    Rev Esp Med Nucl Imagen Mol; 2014 Nov 10; 33(1):22-7. PubMed ID: 23948509
    [Abstract] [Full Text] [Related]

  • 6. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J, Cui XW, Li YS, Wang SY, Yin Q, Wang XN, Gu L.
    Eur Rev Med Pharmacol Sci; 2020 Jul 10; 24(13):7276-7283. PubMed ID: 32706065
    [Abstract] [Full Text] [Related]

  • 7. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F, Alongi P, Evangelista L, Picchio M, Saladini G, Rensi M, Geatti O, Castello A, Laghai I, Popescu CE, Dolci C, Crivellaro C, Seghezzi S, Kirienko M, De Biasi V, Cocciolillo F, Quartuccio N, Young AIMN Working Group.
    Eur J Nucl Med Mol Imaging; 2016 Mar 10; 43(3):404-13. PubMed ID: 26381775
    [Abstract] [Full Text] [Related]

  • 8. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.
    Head Neck; 2018 Jan 10; 40(1):94-102. PubMed ID: 29130586
    [Abstract] [Full Text] [Related]

  • 9. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
    Palomar A, Nanni C, Castellucci P, Ambrosini V, Montini GC, Allegri V, Pettinato C, Al-Nahhas A, Soriano A, Grassetto G, Rubello D, Fanti S.
    Mol Imaging Biol; 2012 Feb 10; 14(1):123-9. PubMed ID: 21240639
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG PET/CT in ovarian cancer recurrence: Clinical impact, correlation with ceCT and CA-125, and prognostic value.
    García-Talavera P, Alejo E, Arias P, Verdú A, Tamayo P, Gómez-Caminero F.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Feb 10; 40(4):207-213. PubMed ID: 34218882
    [Abstract] [Full Text] [Related]

  • 11. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA, Burger IA, Goldman DA, Miccò M, Sosa RE, Weber W, Chi DS, Hricak H, Sala E.
    Eur Radiol; 2015 Nov 10; 25(11):3348-53. PubMed ID: 25916387
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma.
    Xian WJ, Feng YL, Wang Y, Yang M, Lu SN.
    Br J Radiol; 2022 Jan 01; 95(1129):20210279. PubMed ID: 34813375
    [Abstract] [Full Text] [Related]

  • 13. The preoperative SUVmax for (18)F-FDG uptake predicts survival in patients with colorectal cancer.
    Shi D, Cai G, Peng J, Li D, Li X, Xu Y, Cai S.
    BMC Cancer; 2015 Dec 21; 15():991. PubMed ID: 26689966
    [Abstract] [Full Text] [Related]

  • 14. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
    Lopez-Lopez V, Cascales-Campos PA, Gil J, Frutos L, Andrade RJ, Fuster-Quiñonero M, Feliciangeli E, Gil E, Parrilla P.
    Eur J Radiol; 2016 Oct 21; 85(10):1824-1828. PubMed ID: 27666623
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer.
    Lee JE, Kim SW, Kim JS, Choi KY, Kang WK, Oh ST, Yoo IeR, Kim SH.
    World J Gastroenterol; 2012 Sep 28; 18(36):5072-7. PubMed ID: 23049216
    [Abstract] [Full Text] [Related]

  • 16. 18F-FDG PET/CT can predict chemosensitivity and proliferation of epithelial ovarian cancer via SUVmax value.
    Liu S, Feng Z, Wen H, Jiang Z, Pan H, Deng Y, Zhang L, Ju X, Chen X, Wu X.
    Jpn J Radiol; 2018 Sep 28; 36(9):544-550. PubMed ID: 29943313
    [Abstract] [Full Text] [Related]

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Sep 28; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 18. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer.
    Song BI, Kim HW, Won KS, Ryu SW, Sohn SS, Kang YN.
    Medicine (Baltimore); 2015 Jul 28; 94(26):e1037. PubMed ID: 26131811
    [Abstract] [Full Text] [Related]

  • 19. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D, Gill S, Loh N.
    Cancer Med; 2020 Oct 28; 9(20):7469-7476. PubMed ID: 32846054
    [Abstract] [Full Text] [Related]

  • 20. Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: A multicentre study of the FRANCOGYN research group.
    Delvallée J, Rossard L, Bendifallah S, Touboul C, Collinet P, Bricou A, Huchon C, Lavoue V, Body G, Ouldamer L.
    J Gynecol Obstet Hum Reprod; 2020 Nov 28; 49(9):101867. PubMed ID: 32663654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.